Clinical Trial Update: Clinical Study of Neoadjuvant PD-1 Antibody (Toripalimab) Plus Chemotherapy for Locally Advanced Thymic Epithelial Tumor [Phase 2]

View source ↗

Summary

Phase 2 study evaluating neoadjuvant toripalimab (PD-1 antibody) in combination with chemotherapy for locally advanced thymic epithelial tumor.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thymic Epithelial Tumor

Drugs mentioned

• Toripalimab (Toripalimab)

Snippet

Sponsor: Shanghai Pulmonary Hospital, Shanghai, China | Conditions: Thymic Epithelial Tumor | Phase 2 | Status: UNKNOWN